StockpollyBeta
Get App
Popularity #3,386
IPSC · NASDAQ · Biotechnology

Century Therapeutics (IPSC)

Develops iPSC-derived allogeneic cell therapies for autoimmune disease and cancer.

$1.81
vs last close−0.08 (−4.23%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue00111410900000
Cost of revenue2322000002723030
Gross profit−23−221114109−27−230−30
13223236364135814212237
Research & development272323272729272723201420
999888887176
General & administrative999888887176
Other expenses−23−1000040−27−160211
Operating income−36−44−31−35−35−3774−35−36−21−26−37
333443222142
Interest income343433222122
Other non-operating income−4−13−3−4−4−3−2−2−7−1−4−2
Income before tax−32−40−28−31−31−3477−33−34−19−22−35
Income tax expense1−10002000000
Net income from continuing operations−33−39−28−31−31−3677−33−34−19−22−35
Net income−33−39−28−31−31−3677−33−34−19−22−35
EPS, basic−$0.55−$0.66−$0.45−$0.38−$0.37−$0.46$0.89−$0.38−$0.40−$0.22−$0.25−$0.17
EPS, diluted−$0.55−$0.66−$0.45−$0.38−$0.37−$0.46$0.89−$0.38−$0.40−$0.22−$0.25−$0.17
Weighted average shares, basic5960628285798686868787206
Weighted average shares, diluted5960628285798686868787206
EBITDA−28−27−25−28−28−3180−29−26−16−19−35
Depreciation & amortization343333333430
EBIT−32−31−28−31−31−3477−33−29−19−22−35